Nektar Therapeutics (NKTR) Depreciation & Amortization (CF) (2010 - 2026)

Nektar Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $151000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 64.55% year-over-year to $151000.0; the TTM figure through Mar 2026 stood at $685000.0 (down 63.37% YoY), while the FY2025 annual figure was $1.0 million, down 76.63% from the prior year.
• Depreciation & Amortization (CF) was $151000.0 for Q1 2026 at Nektar Therapeutics, down from $190000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.7 million in Q1 2022 to a low of $151000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $1.5 million across 5 years, with a median of $1.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) advanced 5.28% in 2022, then plunged 79.9% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.2 million in 2022, then plunged by 48.08% to $1.7 million in 2023, then slumped by 79.9% to $332000.0 in 2024, then tumbled by 42.77% to $190000.0 in 2025, then dropped by 20.53% to $151000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $151000.0 (Q1 2026), $190000.0 (Q4 2025), and $163000.0 (Q3 2025), per Business Quant data.